HealthQuest picks Korea’s Lunit for first investment in Asia LunitAvery WilliamsNovember 29, 20212021
Everly Health Accelerates Position as Leading Digital Health Company with Acquisition of Women's Health Brand Natalist EverlywellAvery WilliamsOctober 21, 20212021
RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels RareCyteAvery WilliamsSeptember 9, 20212021
Ajax Health Tests New Model for Medtech Innovation With Cordis Ajax III, Ajax HealthAvery WilliamsAugust 5, 20212021
Thirty Madison Raises $140 Million in Series C Financing Led by HealthQuest Capital Thirty MadisonAvery WilliamsJune 4, 20212021
HealthQuest Adds Former Aon Hewitt CEO Kristi Savacool to Its Board of Advisors HealthQuest, SpringbukAvery WilliamsMarch 29, 20212021
Everlywell Acquires PWNHealth and Home Access Health Corporation, Forming Everly Health EverlywellAvery WilliamsMarch 25, 20212021
Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis Alcresta TherapeuticsAvery WilliamsFebruary 24, 20212021
Everlywell's home COVID-19 testing kit goes direct-to-consumer EverlywellAvery WilliamsFebruary 20, 20212021
Perspectum's liver-scanning software scores FDA clearance for planning cancer surgeries PerspectumAvery WilliamsFebruary 1, 20212021
Everlywell raises $75M from HealthQuest Capital following its recent $175M Series D round EverlywellAvery WilliamsJanuary 19, 20212021
Hillrom Announces Planned Acquisition Of Bardy Diagnostics, Inc. Bardy DiagnosticsAvery WilliamsJanuary 19, 20212021
Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million BioTheranosticsAvery WilliamsJanuary 5, 20212021
HealthQuest Adds BD (Becton, Dickinson and Company) Executive Chairman Vince Forlenza to Its Board of Advisors HealthQuestAvery WilliamsJanuary 3, 20212021
TigerConnect Acquires Critical Alert, Ends 2020 with Second Major Acquisition TigerConnectAvery WilliamsJanuary 3, 20212021
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock Castle BiosciencesAvery WilliamsDecember 18, 20202021
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx® Castle BiosciencesAvery WilliamsDecember 14, 20202021
